Navamedic ASA : Navamedic ASA further expands product portfolio.
(Thomson Reuters ONE) -
14 May 2012
Navamedic further expands product portfolio
Navamedic's wholly owned subsidiary Vitaflo Scandinavia has signed a
distribution agreement for the diagnostic product Amnisure. During the last four
months Vitaflo's product portfolio has been expanded by nine new products, to a
total of around 60 patented drugs and healthcare products.
"Navamedic is conuosly working to expand our product portfolio. The new products
included in our portfolio so far in 2012 represent additional annual sales of
more than NOK 8 million. We have not paid any fee for the product rights and the
portfolio expansion supports a continuation of the significant organic sales
growth recently seen in our Vitaflo business area," said Navamedic CEO Olof
Milveden.
Amnisure is a test aimed at identifying ruptures in the fetal membrane of
pregnant women, a condition which can have serious consequences for the mother
and her child. The Amnisure test is recommended by the European Association of
Perinatal Medicine. The product is manufactured by Amnisure International of the
United States. According to the agreement, Vitaflo has taken over the
distribution and is now sole supplier of Amnisure in the Scandinavian markets.
Navamedic's subsidiary Vitaflo is a Nordic distributor of approximately 60
patented drugs and health care products from more than 20 manufacturers. The
company saw a 29 per cent sales growth in 2011 followed by a 22 per cent sales
growth in the first quarter 2012.
For further information, please call Olof Milveden, CEO, telephone
+46 733 463 736.
Navamedic ASA is a Norwegian pharmaceutical products company. Through its
subsidiary Vitaflo Scandinavia the Company is a distributor of a broad range of
nutrition and pharmaceutical products in the Nordic markets. Navamedic is
currently building up a generic pharmaceutical business for the Nordic, Dutch
and Belgian markets based on its partnership with Aspen Healthcare of South
Africa. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Navamedic ASA via Thomson Reuters ONE
[HUG#1611911]
Unternehmensinformation / Kurzprofil:
Datum: 14.05.2012 - 15:54 Uhr
Sprache: Deutsch
News-ID 146196
Anzahl Zeichen: 2814
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 237 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Navamedic ASA : Navamedic ASA further expands product portfolio."
steht unter der journalistisch-redaktionellen Verantwortung von
Navamedic ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
